Stories about medicine
1 related stories
“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
AI InsightVijay Pande, after leaving a16z's biotech practice, shifts his focus to investing in AI-native company VZVC, emphasizing the shift of biology from a 'discovery' science to an 'engineering' one, and the importance of open, shared datasets for AI's application in medicine.Key TakeawayVijay Pande shifts his investment focus from biotech to AI-native companies and emphasizes the importance of data sharing for AI's application in medicine.Why It MattersThis shift signifies a more data-sharing and engineering-focused approach to AI in medicine, potentially accelerating the development of medical AI.Who's Affected- AI ResearchersAI researchers will benefit from open, shared datasets, which may promote the development of medical AI.
- InvestorsInvestors may be interested in investment opportunities in AI-native companies.
- Medical IndustryThe medical industry may accelerate the adoption of AI technologies.
What's NextFuture attention can be focused on the development of VZVC and specific application cases of AI in the medical field.Importance 60/100